ESC Abstract #84183First Descriptive Study of Demographic and Clinical Characteristics of US Patients Using Icosapent Ethyl: Cross-sectional analysis

of demographic clinical characteristics of patients using icosapent ethyl presented by myself at ESC 2023 Congress in Amsterdam,Netherlands on behalf of co-authors P.Toth,H.Soran,O.Ganda,H.Hannachi,N.Wong,D.Abrahamson,J.Hartman and S.Philip on August 27th,2023

We looked at a database with electronic records of >89 million patients from 56 US health care organizations to identify those taking IPE.(defined as those for whom at least 2 IPE prescriptions were documented--ie,on 2 separate dates)

As of January 19th,2023 ,a total of 40,408 patients taking IPE were identified.In line with the indication of IPE,65.3% had prior atherosclerotic CVD or DM and at least 1risk factor

Common prior or existing conditions associated with those indicated for treatment were DM(41%),CAD(30.2%),prior MI(11.0%),prior stroke (7.4%),severe hypertriglyceridemia(8.1%),HTN(68.4%) and obesity(40.9%).

Treatment with statins was (71.8%),anticoagulants(53.3%),antidiabetic agents(52.3%)and antiplatelets(46.0%).Fibrates were used by 26% of patients taking IPE any time on or before IPE initiation.

Mean (SD;median)TG level in the 3 months before IPE initiation was 422mg/dl (506;300).

Conclusions: "Patients using IPE commonly had a history of CVD,DM or both,took statins,and had elevated levels of TG,thereby meeting the indication for IPE treatment.The high baseline TG levels in this population suggest that IPE is underutilized"

On a personal level as someone who is in the trenches treating patients on a daily basis for over 30 years, witnessing this Real World data for the first time,although shocking (TG level of 422mg/dl !!!!!)was not surprising.There needs to be increased focus by Providers to include prescription IPE as per guideline recommendations.The impact of total CVD event reduction in REDUCE-IT is substantial;for every 1,000 patients treated with IPE for 5 years,approximately 159 total primary endpoints could be PREVENTED including 12 CV deaths,42 MI's,14 strokes,76 coronary revascularizations,and 16 episodes of hospitalization for unstable angina(Bhatt DL et al.JACC.2019;73(22):2791-2802)We should be putting the same energy that we place on statin treatment as for IPE treatment !!!